Senior doctors at Belfast Trust raised concerns over culture 18 months ago
The doctors warned that some medics were so upset by their treatment by management that they were left feeling suicidal.
The claims were made during a meeting in January 2024 between a large number of doctors and consultants from across the Belfast Trust and the organisation's former chairman Ciaran Mulgrew.
Mr Mulgrew was not the subject of any of the concerns raised by the doctors.
Details of the meeting were outlined in a follow up letter from the group to Mr Mulgrew.
The letter, seen by UTV, mentioned how some doctors were in tears during the meeting as they outlined their experiences.
The correspondence also claimed there had been "clear reference to suicidal ideation amongst consultant staff" who had been subjected to internal disiplinary procedures, known as the Maintaining High Professional Standards process (MHPS).
One consultant told the meeting: 'it is only by good fortune that we had not had a colleague commit suicide due to the ordeal.'
Concern was also raised "regarding the culture and perceived lack of psychological safety in the environment in which consultant medical staff work in the BHSCT.'
Allegations were also made in the letter that in some cases doctors were placed under the disciplinary process after "raising whistleblowing concerns around patient safety."
In a statement the Belfast Trust said: "Belfast Trust supports all staff who wish to tell us of their experiences and we have offered a number of options for them to do so.
"We encourage staff to talk to us and we also have a firm commitment to our whistleblowing policy.
"We are providing bespoke training, and communicate daily with staff, focusing on patient safety in addition to having dedicated weekly governance meetings.
"We continue to work diligently to ensure that we make tangible improvements across the organisation, and in particular, within cardiac surgery services."
The Department of Health said: "The Department can confirm that the Permanent Secretary met with the non-executive directors of Belfast Trust on Monday evening.
"The Department will continue to provide support for the Trust as it deals with a series of significant challenges including service and funding pressures, governance issues and workplace culture.
"The Department has engaged with the Trust over a number of years in relation to its challenges.
"Following completion of the independent review of the Trust's cardiac surgery unit, Departmental intervention under its Support and Intervention Framework (SIF) was escalated to Level 5, the highest level.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
2 days ago
- Reuters
Sarepta shares slump after reports of third patient death this year
July 18 (Reuters) - Shares of Sarepta Therapeutics (SRPT.O), opens new tab declined 26% to $16.17 in premarket trading on Friday on media reports of a patient death after receiving one of the company's gene therapies, making it the third such fatality this year. The patient was enrolled in an early-stage study testing Sarepta's gene therapy to treat a condition called limb-girdle muscular dystrophy, according to a Bloomberg report, which cited a company spokesperson. STAT news reported that the patient was a 51-year-old man who died last month from acute liver failure. Two teenage boys, who couldn't walk independently, died earlier this year from liver failure after they received Sarepta's gene therapy Elevidys, approved to treat a rare condition called Duchenne muscular dystrophy. Sarepta and the Department of Health and Human Services did not immediately respond to a Reuters request for comment outside of their business hours. The fatalities have brought Sarepta under heightened regulatory scrutiny, and cast doubts on the safety and future demand for Elevidys. William Blair analyst Sami Corwin said this could amplify patient hesitancy to use Elevidys and increase investor distrust since Sarepta did not disclose the latest fatality on a call earlier this week. The company said on Wednesday it had halted development of several gene therapies for limb-girdle muscular dystrophy, a group of genetic disorders that primarily weaken the hip and shoulder muscles. Sarepta had also said it planned to present mid-stage data for its gene therapy, SRP-9003, for the disorder later this year, which will be included in its marketing application to the U.S. Food and Drug Administration. Corwin added the news of the third patient death could also lead to greater scrutiny over the safety of SRP-9003. Sarepta plans to cut 500 jobs and add a serious warning on the label of Elevidys for the risk of acute liver injury and liver failure in DMD patients who can walk.
BBC News
4 days ago
- BBC News
Dedicated Wolverhampton school nurse retires after 50 years
A "much loved" school nurse in Wolverhampton is retiring after a 50-year career in the Thomas has spent the past five decades devoted to the health and wellbeing of children and families across the city, the Royal Wolverhampton NHS Trust has spent the last 38 years as a school nurse in Bilston, finding herself caring for the children of the parents she once looked described her career as "the privilege of a lifetime" adding that she will miss all her colleagues, parents and the children. Her career started in August 1975 as a cadet at New Cross Hospital before working in microbiology and on the children's ward at the former Royal Hospital."In 1976 I worked at Penn Children's Hospital which was eye opening - caring for some of the most vulnerable," she also also spent some time working at the city's Eye Infirmary."It was very strict there - you would have to stand up every time a matron came into the room. I learnt a lot there," she then moved into school nursing in June 1986. 'So much care and compassion' "When I see the sons and daughters of former children I was a nurse for coming through the doors, I feel such joy knowing I've been part of their family's journey for generations," she said."I will really miss my colleagues - we feel like one big family. They are all fantastic and do an amazing job."I will miss everything about the job - the parents, the children and the staff."Emma Jones, group management PA for children's community services and children and young people in care (CYPIC), said Mrs Thomas was her school nurse as she was growing up in Bilston and said she would be missed by everyone."I remember her being someone that was always there to offer help, guidance and support to myself and other pupils at school. She demonstrated so much care and compassion," she said."Now looking at things from a different perspective, I have been working with the School Nursing Service for 15 years and Julie's passion and dedication to her role has remained consistent through the years."Hazel Hawkins-Dady, matron for School Nursing, thanked her for her dedication and added that the team wished her every happiness in her new chapter. Follow BBC Wolverhampton & Black Country on BBC Sounds, Facebook, X and Instagram.
Leader Live
7 days ago
- Leader Live
DIY heart monitor rolled out to cut hospital waiting lists
Traditional monitors can require lengthy set-up by a trained physiologist, but the new kit can be sent out to patients in the post for them to attach themselves at home. The device looks like a small patch which is stuck to the skin, while traditional devices see patients hooked up to numerous wires and monitors. After the new tool is worn for a few days, patients can post the device back – which will cut out the need for appointments to fit and remove the equipment. The information from the monitor is then assessed using an artificial intelligence (AI) tool, Cardiologs, which produces a report which is then assessed by either a physiologist or a doctor. It can be used to investigate conditions include atrial fibrillation, tachycardia or heart blocks. Frimley Health NHS Foundation Trust is the first hospital in the country to roll out the device, with hopes that the device will soon be used across other NHS trusts. The Trust said it will still use traditional devices, known as Holter monitors, on some patients who are in hospital, but many of those who are outside of hospital will be able to access the new ePatch, which is made by Philips, to use in the comfort of their own homes. It has estimated that the use of the patches will double its productivity levels for diagnosing heart rhythm problems. Dr Iain Sim, consultant cardiac electrophysiologist, told the PA news agency: 'The purpose of the device is to record the heart rhythm – to collect electrical signals from the heart – and to try to understand a bit about the patient and what they are experiencing and whether that can be explained by their heart rhythm. 'This smaller device allows us to measure at the moment up to 10 days 'The benefits of it are that it is smaller and more convenient, rather than different wires all over the place. 'We are able to put them on faster and we're able to reduce our turnaround times for reports and to get results back to patients faster.' He said that traditional Holter monitors are attached by trained physiologists but there is a shortage of these staff members at present. 'Because these are more straightforward, we've got specialist nurses who can be quite easily trained to apply them,' he added. Suzanne Jordan, associate director for medicine at Frimley Health, said the patches can even be sent out to patients for them to attach themselves. The feedback from the monitors are developed into reports for medics which are categorised in a traffic light system, she said. 'Green is perfectly fine – within normal limits; amber may need a clinician to review the report; red means potentially significant pauses or arrhythmia that need kind of an urgent review,' she said. 'It's been really positive – staff and patients really like it. 'We can post the patches to patients – there's explicit instructions there in terms of how to put it on, what to do if there's a problem, and also just to send it back as well. 'Once it comes back, it gets downloaded and the turnaround times are great.' Ms Jordan added: 'If you think of the bigger picture, it means that we're going to be able to manage our patients quickly. 'We've been running clinics by seeing maybe 30 patients in one day, whereas before, we were probably seeing 14 maximum – so we've kind of doubled our productivity. Asked about the conditions which will be monitored with the devices, Dr Sim added: 'Atrial fibrillation (AF) is a really important and common condition that we pick up with these devices, and we're increasingly looking at whether we can use them to help detect AF that's not symptomatic, and whether people are increased risk of stroke that we don't know about. 'The other conditions would relate to other forms of types of tachycardia, so fast heart rates, or episodes of very slow heart rates, such as heart blocks of different degrees, where patients may have palpitations or they may have fainting or syncope. 'So it allows us to monitor all of those heart rhythms.' On the use of AI to review the data from the monitors, he added: 'I think it's natural for everyone to be concerned whenever you put the term 'AI' into something, but these are pretty well tested algorithms that still have human oversight.' Mark Leftwich, managing director for Philips UK and Ireland, said: 'We're really excited to be working with Frimley Health to make heart monitoring easier and more comfortable for patients. 'Studies show Philips ePatch can spot up to 2.5 times more clinically relevant heart rhythm issues than the traditional Holter monitors – so not only is it more comfortable to wear, it can actually help catch issues that might have been missed before.'
